

Tuberculosis profile: Timor-Leste

Population 2021: 1.3 million

Estimates of TB burden*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	6 400 (4 300-9 000)	486 (322-684)
HIV-positive TB incidence	67 (37-110)	5.1 (2.8-8)
MDR/RR-TB incidence**	57 (11-100)	4.3 (0.8-7.8)
HIV-negative TB mortality	1 200 (760-1 800)	94 (57-140)
HIV-positive TB mortality	13 (8-19)	0.97 (0.59-1.4)

Estimated proportion of TB cases with MDR/RR-TB*, 2021

New cases	0.65% (0.26-1.3)
Previously treated cases	4.8% (1.3-12)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2021	50% (35-75)
TB patients facing catastrophic total costs, 2017	83% (80-86)
TB case fatality ratio (estimated mortality/estimated incidence), 2021	20% (10-33)

TB case notifications, 2021

Total new and relapse	3 193
- % tested with rapid diagnostics at time of diagnosis	32%
- % with known HIV status	93%
- % pulmonary	84%
- % bacteriologically confirmed [^]	58%
- % children aged 0-14 years	6%
- % women (aged ≥15 years)	41%
- % men (aged ≥15 years)	53%
Total cases notified	3 268

TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	31	1%
- on antiretroviral therapy	31	100%

Drug-resistant TB care**, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	1.3%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	0%
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	20
Patients started on treatment - MDR/RR-TB ^{^^^}	19
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	0

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	91%	3 225
Previously treated cases, excluding relapse, registered in 2020	86%	70
HIV-positive TB cases registered in 2020	90%	42
MDR/RR-TB cases started on second-line treatment in 2019	100%	9
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019		0


TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (95-100)


Funding for TB

Funding for TB, 2021 (US\$ millions)	10
- % domestic funding	0%
- % international funding	100%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




HIV-negative TB mortality (Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2021 (Number)



Cases attributable to five risk factors, 2021 (Number)



Funding for TB (US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
** RR is TB resistant to rifampicin (R), MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
^ Calculated for pulmonary cases only
^^ Includes cases with unknown previous TB treatment history
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed

Generated 2022-11-28 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)